Skip to main navigation
Skip to search
Skip to main content
Albert Einstein College of Medicine Home
Search content at Albert Einstein College of Medicine
Home
Faculty
Departments
Grants
Publications
Prizes
Preventive Treatment of Migraine
Richard B. Lipton
Neurology
Research output
:
Contribution to journal
›
Review article
›
peer-review
10
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Preventive Treatment of Migraine'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Migraine Treatment
100%
Preventive Treatment
100%
Calcitonin Gene-related Peptide
71%
Monoclonal Antibody
42%
Acute Treatment
42%
Peptide Target
42%
Tolerability
28%
Episodic Migraine
28%
Targeted Therapy
28%
Ubrogepant
28%
Atogepant
28%
Zavegepant
28%
Headache
14%
Drug Target
14%
Health-related Quality of Life
14%
Migraine
14%
Chronic Migraine
14%
Disability
14%
Migraine Medication
14%
Medication Overuse
14%
Self-efficacy
14%
Good Safety
14%
Novel Paradigm
14%
Preventive Migraine Treatment
14%
Interictal Burden
14%
Targeted Medication
14%
Self-health
14%
Erenumab
14%
Galcanezumab
14%
Fremanezumab
14%
Eptinezumab
14%
Rimegepant
14%
Oral Small Molecules
14%
Evidence of Effectiveness
14%
Gepants
14%
Calcitonin Gene-related Peptide Receptor Antagonist
14%
Medicine and Dentistry
Migraine
100%
Calcitonin Gene Related Peptide
62%
Monoclonal Antibody
37%
Targeted Therapy
25%
Episodic Migraine
25%
Ubrogepant
25%
Atogepant
25%
Quality of Life
12%
Headache
12%
Transformed Migraine
12%
Medication Overuse
12%
Self Concept
12%
Calcitonin Gene-Related Peptide Receptor Antagonist
12%
Eptinezumab
12%
Galcanezumab
12%
Erenumab
12%
Fremanezumab
12%
Rimegepant
12%
Oral
12%
Drug Targeting
12%
Pharmacology, Toxicology and Pharmaceutical Science
Migraine
100%
Calcitonin Gene Related Peptide
62%
Monoclonal Antibody
37%
Episodic Migraine
25%
Tolerability
25%
Ubrogepant
25%
Atogepant
25%
Headache
12%
Transformed Migraine
12%
Medication Overuse
12%
Drug Delivery System
12%
Calcitonin Gene Related Peptide Receptor Antagonist
12%
Eptinezumab
12%
Galcanezumab
12%
Erenumab
12%
Fremanezumab
12%
Rimegepant
12%